Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)

The aim of this study was to evaluate the usefulness of EGFR mutation status in serum DNA as a means of predicting a benefit from gefitinib (IRESSA) therapy in Japanese patients with non-small cell lung cancer (NSCLC). We obtained pairs of tumour and serum samples from 42 patients treated with gefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, H, Suminoe, M, Kasahara, K, Sone, T, Araya, T, Tamori, S, Koizumi, F, Nishio, K, Miyamoto, K, Fujimura, M, Nakao, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360394/
https://www.ncbi.nlm.nih.gov/pubmed/17848912
http://dx.doi.org/10.1038/sj.bjc.6603949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360394/
https://www.ncbi.nlm.nih.gov/pubmed/17848912
http://dx.doi.org/10.1038/sj.bjc.6603949

Ejemplares similares